Identifai Genetics Limited IPO: Date, Status and What We Know
IPO facts
- Status
- Priced
- Market
- Australia
- Country
- Australia
- Exchange
- ASX (Australian Securities Exchange)
- Ticker
- ID1
- Sector
- Medical technology (prenatal genetic screening)
- Expected timing
- Trading anticipated on 13 October 2026 by the ASX; the prospectus indicates 16 October 2026
- Filing date
- Book-building
- –
- First trading day
- Offer price
- A$0.20 per share
- Offering size
- AUD 10 million · 50,000,000 shares
- Last valuation
- AUD 38.4 millionindicative market capitalisation at listing, undiluted, at the offer price (prospectus), 2 September 2026; source: identifai-genetics.com
About Identifai Genetics Limited
Identifai Genetics, through its Israeli subsidiary, is developing Windrose, a non-invasive prenatal screening platform that combines whole-genome sequencing, bioinformatics and AI using a single maternal blood sample.
IPO notes
Identifai lodged its prospectus with ASIC on 2 September 2026 for an offer of 50,000,000 shares at A$0.20 each, or A$10 million; the offer opened on 10 September and closed on 29 September 2026 (identifai-genetics.com). The prospectus puts the indicative market capitalisation at listing at about A$38.4 million on an undiluted basis and indicates trading from 16 October 2026, while the ASX upcoming floats page anticipates 13 October 2026 at 11:00am AEDT (asx.com.au). The offer is not underwritten, with Aesir Corporate as lead manager.
Other IPOs in this market
Sources
- identifai-genetics.com · Prospectus (lodged 2 Sep 2026): offer terms, timetable, capital structure ·
- asx.com.au · Upcoming floats and listings page: anticipated listing date 13 Oct 2026 ·
Named as plain text with what each source states and the date it was checked.